PER 1.41% 7.0¢ percheron therapeutics limited

Ann: Company Update, page-110

  1. 35,730 Posts.
    lightbulb Created with Sketch. 554
    You do realise where Roche paid $65M up-front mid Phase III trial Chiasma had raised $38.5M to finish the Phase III a few months earlier & $21M the year before to get it underway right ?

    Funny what the number comes to when you take the Phase III funding out ?

    Always open to surprises though
 
watchlist Created with Sketch. Add PER (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.